摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[(3-ethyl-1-oxido-1,2,4-benzotriazin-6-yl)oxy]-N,N-dimethylethaneamine | 863973-52-8

中文名称
——
中文别名
——
英文名称
2-[(3-ethyl-1-oxido-1,2,4-benzotriazin-6-yl)oxy]-N,N-dimethylethaneamine
英文别名
2-[(3-ethyl-1-oxido-1,2,4-benzotriazin-1-ium-6-yl)oxy]-N,N-dimethylethanamine
2-[(3-ethyl-1-oxido-1,2,4-benzotriazin-6-yl)oxy]-N,N-dimethylethaneamine化学式
CAS
863973-52-8
化学式
C13H18N4O2
mdl
——
分子量
262.312
InChiKey
QNLSKOFRZUBMFH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    19
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    63.7
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-[(3-ethyl-1-oxido-1,2,4-benzotriazin-6-yl)oxy]-N,N-dimethylethaneamine双氧水三氟乙酸三氟乙酸酐 作用下, 以 二氯甲烷 为溶剂, 反应 16.17h, 以32%的产率得到2-[(3-ethyl-1,4-dioxido-1,2,4-benzotriazin-6-yl)oxy]-N,N-dimethylethaneamine
    参考文献:
    名称:
    [EN] NOVEL 1,2,4-BENZOTRIAZINE-1,4-DIOXIDES
    [FR] 1,2,4-BENZOTRIAZINE-1,4-DIOXYDES
    摘要:
    本发明提供了一种简化的特征集,可用于选择对人类肿瘤异种移植物中的缺氧细胞具有治疗活性的1,2,4-苯并三氮唑-1,4-二氧化物(TPZ类似物),并进一步提供了一种新型的1,2,4-苯并三氮唑-1,4-二氧化物(TPZ类似物),预测其对肿瘤的体内活性,以及它们的制备和用作缺氧选择性细胞毒药物和放射增敏剂用于癌症治疗,单独或与放射线和/或其他抗癌药物结合使用。
    公开号:
    WO2005082867A1
  • 作为产物:
    描述:
    3-ethyl-6-fluoro-1,2,4-benzotriazine 1-oxideN,N-二甲基乙醇胺sodium 作用下, 反应 2.5h, 以59%的产率得到2-[(3-ethyl-1-oxido-1,2,4-benzotriazin-6-yl)oxy]-N,N-dimethylethaneamine
    参考文献:
    名称:
    [EN] NOVEL 1,2,4-BENZOTRIAZINE-1,4-DIOXIDES
    [FR] 1,2,4-BENZOTRIAZINE-1,4-DIOXYDES
    摘要:
    本发明提供了一种简化的特征集,可用于选择对人类肿瘤异种移植物中的缺氧细胞具有治疗活性的1,2,4-苯并三氮唑-1,4-二氧化物(TPZ类似物),并进一步提供了一种新型的1,2,4-苯并三氮唑-1,4-二氧化物(TPZ类似物),预测其对肿瘤的体内活性,以及它们的制备和用作缺氧选择性细胞毒药物和放射增敏剂用于癌症治疗,单独或与放射线和/或其他抗癌药物结合使用。
    公开号:
    WO2005082867A1
点击查看最新优质反应信息

文献信息

  • Novel 1,2,4-benzotriazine-1,4-dioxides
    申请人:Denny Alexander William
    公开号:US20070197534A1
    公开(公告)日:2007-08-23
    The present invention provides a simplified set of characteristics that can be used to select 1,2,4 benzotriazine 1,4 dioxide compounds (TPZ analogues) with therapeutic activity against hypoxic cells in human tumour xenografts, and to further provide a novel class of 1,2,4-benzotriazine-1,4-dioxides (TPZ analogues) with predicted in vivo activity against tumours, to their preparation, and to their use as hypoxia-selective cytotoxic drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
    本发明提供了一组简化的特征,可用于选择对人类肿瘤异种移植物中的低氧细胞具有治疗活性的1,2,4-苯并三氮唑-1,4-二氧化物化合物(TPZ类似物),并进一步提供一种新型的1,2,4-苯并三氮唑-1,4-二氧化物(TPZ类似物),预测其对肿瘤的体内活性,以及它们的制备和作为低氧选择性细胞毒性药物和放射增敏剂用于癌症治疗,单独或与放射线和/或其他抗癌药物联合使用。
  • 1,2,4-benzotriazine-1,4-dioxides
    申请人:Auckland Uniservices Limited
    公开号:US07816521B2
    公开(公告)日:2010-10-19
    The compound 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide and pharmacologically acceptable salts thereof. A method of treating cancer in a subject is also described in which 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide or a pharmacologically acceptable salt thereof is administered to tumor cells in a hypoxic environment. Also described is a method of radiosensitising in a subject tumor cells of solid tumors in hypoxic conditions by administering to the subject a pharmaceutical composition containing 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide or a pharmacologically acceptable salt thereof in an amount sufficient to produce radiosensitivity in the tumor cells, and subjecting the tumor cells to radiation. A pharmaceutical composition is additionally provided containing a therapeutically effective amount of 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide or a pharmacologically acceptable salt thereof and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabiliser.
    本文描述了化合物3-乙基-6-[3-(4-吗啡啶基)丙氧基]-1,2,4-苯并三氮唑1,4-二氧化物及其药学上可接受的盐。还描述了一种治疗受体癌症的方法,其中3-乙基-6-[3-(4-吗啡啶基)丙氧基]-1,2,4-苯并三氮唑1,4-二氧化物或其药学上可接受的盐被用于在低氧环境下治疗肿瘤细胞。此外,还提供了一种方法,通过向患者注射含有3-乙基-6-[3-(4-吗啡啶基)丙氧基]-1,2,4-苯并三氮唑1,4-二氧化物或其药学上可接受的盐的药物组合物,以在低氧条件下使实体瘤中的肿瘤细胞放射敏感性,然后将肿瘤细胞暴露于放射线。此外,还提供了一种药物组合物,其中包含治疗有效量的3-乙基-6-[3-(4-吗啡啶基)丙氧基]-1,2,4-苯并三氮唑1,4-二氧化物或其药学上可接受的盐和药学上可接受的赋形剂、辅料、载体、缓冲剂或稳定剂。
  • Hypoxia-Selective 3-Alkyl 1,2,4-Benzotriazine 1,4-Dioxides: The Influence of Hydrogen Bond Donors on Extravascular Transport and Antitumor Activity
    作者:Michael P. Hay、Karin Pchalek、Frederik B. Pruijn、Kevin O. Hicks、Bronwyn G. Siim、Robert F. Anderson、Sujata S. Shinde、Victoria Phillips、William A. Denny、William R. Wilson
    DOI:10.1021/jm701037w
    日期:2007.12.27
    Tirapazamine (TPZ) and related 1,2,4-benzotriazine 1,4 dioxides (BTOs) are selectively toxic under hypoxia, but their ability to kill hypoxic cells in tumors is generally limited by their poor extravascular transport. Here we show that removing hydrogen bond donors by replacing the 3-NH2 group of TPZ with simple alkyl groups increased their tissue diffusion coefficients as measured in multicellular layer cultures. This advantage was largely retained using solubilizing 3-alkylaminoalkyl substituents provided these were sufficiently lipophilic at pH 7.4. The high reduction potentials of such compounds resulted in rates of metabolism too high for optimal penetration into hypoxic tissue, but electron-donating 6- and 7-substituents moderated metabolism. Pharmacokinetic/pharmacodynamic model-guided screening was used to select BTOs with optimal extravascular transport and hypoxic cytotoxicity properties for evaluation against HT29 human tumor xenografts in combination with radiation. This identified four novel 3-alkyl BTOs providing greater clonogenic killing of hypoxic cells than TPZ at equivalent host toxicity, with the 6-morpholinopropyloxy-BTO 22 being 3-fold more active.
  • US7816521B2
    申请人:——
    公开号:US7816521B2
    公开(公告)日:2010-10-19
  • [EN] NOVEL 1,2,4-BENZOTRIAZINE-1,4-DIOXIDES<br/>[FR] 1,2,4-BENZOTRIAZINE-1,4-DIOXYDES
    申请人:AUCKLAND UNISERVICES LTD
    公开号:WO2005082867A1
    公开(公告)日:2005-09-09
    The present invention provides a simplified set of characteristics that can be used to select 1,2,4 benzotriazine 1,4 dioxide compounds (TPZ analogues) with therapeutic activity against hypoxic cells in human tumour xenografts, and to further provide a novel class of 1,2,4-benzotriazine-1,4-dioxides (TPZ analogues) with predicted in vivo activity against tumours, to their preparation, and to their use as hypoxia-selective cytotoxic drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
    本发明提供了一种简化的特征集,可用于选择对人类肿瘤异种移植物中的缺氧细胞具有治疗活性的1,2,4-苯并三氮唑-1,4-二氧化物(TPZ类似物),并进一步提供了一种新型的1,2,4-苯并三氮唑-1,4-二氧化物(TPZ类似物),预测其对肿瘤的体内活性,以及它们的制备和用作缺氧选择性细胞毒药物和放射增敏剂用于癌症治疗,单独或与放射线和/或其他抗癌药物结合使用。
查看更多